FDA reviewers on Ipsen's potential ultra-rare disease drug: Post-hoc analysis may be enough
Post-hoc analyses are generally a major no-no for the FDA, but agency reviewers signaled their openness to considering them in the case of Ipsen’s potential …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
